HCWB

Company Overview — What Does HCW Biologics Inc. Do?

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida. HCW Biologics Inc. (HCWB) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Hing C. Wong and employs approximately 40 people. With a market capitalization of $1M, HCWB is one of the notable companies in the Healthcare sector.

HCW Biologics Inc. (HCWB) Stock Rating — Avoid (April 2026)

As of April 2026, HCW Biologics Inc. receives a Avoid rating with a composite score of 19.6/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.HCWB ranks #4,424 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, HCW Biologics Inc. ranks #827 of 839 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

HCWB Stock Price and 52-Week Range

HCW Biologics Inc. (HCWB) currently trades at $0.27. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is HCWB Overvalued or Undervalued? — Valuation Analysis

HCW Biologics Inc. (HCWB) carries a value factor score of 8/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.38x, versus the sector average of 2.69x. The price-to-sales ratio is 2.33x, compared to 1.64x for the average Healthcare stock.

At current multiples, HCW Biologics Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

HCW Biologics Inc. Profitability — ROE, Margins, and Quality Score

HCW Biologics Inc. (HCWB) earns a quality factor score of 12/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -455.1%, compared to the Healthcare sector average of -42.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -51.3% versus the sector average of -33.1%.

On a margin basis, HCW Biologics Inc. reports gross margins of 20.0%, compared to 71.3% for the sector. The operating margin is -28414.7% (sector: -65.2%). Net profit margin stands at -25725.7%, versus -54.1% for the average Healthcare stock. Revenue growth is running at -97.5% on a trailing basis, compared to 10.7% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

HCWB Debt, Balance Sheet, and Financial Health

HCW Biologics Inc. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 31.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 0.11x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $0. Cash and equivalents stand at $1M.

HCWB has a beta of 17.90, meaning it is more volatile than the broader market — a $10,000 investment in HCWB would be expected to move 1689.7% more than the S&P 500 on any given day. The stability factor score for HCW Biologics Inc. is 1/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

HCW Biologics Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, HCW Biologics Inc. reported revenue of $453,644 and earnings per share (EPS) of $-10.63. Net income for the quarter was $-13M. Gross margin was 20.0%. Operating income came in at $-12M.

In FY 2025, HCW Biologics Inc. reported revenue of $54,232 and earnings per share (EPS) of $-10.63. Net income for the quarter was $-8M. Gross margin was 20.0%. Revenue grew -97.9% year-over-year compared to FY 2024. Operating income came in at $-13M.

In Q3 2025, HCW Biologics Inc. reported revenue of $15,606 and earnings per share (EPS) of $-2.02. Net income for the quarter was $-5M. Gross margin was 20.0%. Revenue grew -96.3% year-over-year compared to Q3 2024. Operating income came in at $-3M.

In Q2 2025, HCW Biologics Inc. reported revenue of $6,550 and earnings per share (EPS) of $-6.79. Net income for the quarter was $-2M. Gross margin was 20.0%. Revenue grew -98.9% year-over-year compared to Q2 2024. Operating income came in at $-3M.

Over the past 8 quarters, HCW Biologics Inc. has experienced revenue contraction from $618,854 to $453,644. Investors analyzing HCWB stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

HCWB Dividend Yield and Income Analysis

HCW Biologics Inc. (HCWB) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

HCWB Momentum and Technical Analysis Profile

HCW Biologics Inc. (HCWB) has a momentum factor score of 39/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 10/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

HCWB vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, HCW Biologics Inc. (HCWB) ranks #827 out of 839 stocks based on the Blank Capital composite score. This places HCWB in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.5/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.3/100, HOLOGIC INC (HOLX) with a score of 52.8/100, FONAR CORP (FONR) with a score of 53.0/100, and Royalty Pharma plc (RPRX) with a score of 53.4/100.

Comparing HCWB against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full HCWB vs S&P 500 (SPY) comparison to assess how HCW Biologics Inc. stacks up against the broader market across all factor dimensions.

HCWB Next Earnings Date

No upcoming earnings date has been announced for HCW Biologics Inc. (HCWB) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy HCWB? — Investment Thesis Summary

The quantitative profile for HCW Biologics Inc. suggests caution. The quality score of 12/100 flags below-average profitability. The value score of 8/100 indicates premium valuation. Momentum is weak at 39/100, a headwind for near-term performance. High volatility (stability score 1/100) increases portfolio risk.

In summary, HCW Biologics Inc. (HCWB) earns a Avoid rating with a composite score of 19.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on HCWB stock.

Related Resources for HCWB Investors

Explore more research and tools: HCWB vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare HCWB head-to-head with peers: HCWB vs AZN, HCWB vs SLGL, HCWB vs HOLX.